Innovative Precision Medicine: Ayla Annac's Journey at InvivoSciences

Introduction of InvivoSciences: Ayla Annac, co-founder and CEO of InvivoSciences, discusses the company's focus on developing therapies for cardiovascular and cardiometabolic diseases through innovative precision medicine technology.

Personal Motivation: Ayla’s passion for addressing cardiovascular diseases stems from the personal loss of her father to heart disease at a young age, which motivated her to pursue solutions in this medical field.

Technological Innovation: InvivoSciences utilizes a proprietary platform named Cordia for drug discovery and to identify subpopulations that match specific drugs, enhancing the effectiveness and safety of medications.

Challenges and Perseverance: Ayla highlights the financial and industry challenges in drug development, emphasizing the need for increased investment and collaboration within the sector to bring innovative treatments to market.

Vision and Future Goals: Ayla's mission extends beyond her company to push for a broader adoption of precision medicine in cardiovascular treatment, aiming to develop effective drugs that can significantly reduce the impact of heart diseases globally.